IASLC-TTLC 2023 - IASLC 2023 Targeted Therapies of Lung Cancer Meeting
Feb 22 - Feb 25, 2023 | Santa MonicaCAUS
LARVOL is not affiliated with IASLC 2023 Targeted Therapies of Lung Cancer Meeting and all trademarks, logos, and brand names are property of their respective owners
Showing 7 abstracts linked to Trials
Pivotal Data Update from the Phase 1/2 TRIDENT-1 Trial of Repotrectinib in Patients with ROS1+ Advanced Non-Small Cell Lung Cancer (NSCLC)
Risk of Further Progression or Death among Durable Progression-Free Survivors with Non-Small Cell Lung Cancer in PD-1 Blockade Trials: Guidance on Imaging Surveillance Interval
A Phase 1 Trial of BI 1810631, a HER2 Tyrosine Kinase Inhibitor (TKI), as Monotherapy in Patients with Advanced/Metastatic Solid Tumors with HER2 Aberrations
Phase II Trial of Regorafenib and Oral Methotrexate in Previously Treated Advanced KRAS Mutant Non-Small Cell Lung Cancer
Plasma PCSK9 levels in patients receiving neoadjuvant pembrolizumab in resectable non-small cell lung cancer (NSCLC)
BASECAMP-1: Leveraging Human Leukocyte Antigen A (HLA-A) Loss of Heterozygosity (LOH) in Solid Tumors by Next-Generation Sequencing (NGS) to Identify Patients With Relapsed Solid Tumors for Carcinoembryonic Antigen (CEA) and Mesothelin (MSLN) Logic-Gated Tmod™ Chimeric Antigen Receptor (CAR) T-Cell Therapy
Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase (TRK) Fusion Lung Cancer by Prior Line of Systemic Therapy and Performance Status